Separately, HC Wainwright reiterated a “buy” rating and set a $11.00 price objective on shares of Galectin Therapeutics in a research note on Tuesday, August 15th.
Galectin Therapeutics Stock Performance
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently modified their holdings of GALT. Summit Trail Advisors LLC acquired a new stake in Galectin Therapeutics during the 2nd quarter valued at $29,000. Citadel Advisors LLC increased its holdings in Galectin Therapeutics by 269.5% during the 3rd quarter. Citadel Advisors LLC now owns 18,140 shares of the company’s stock valued at $29,000 after purchasing an additional 28,840 shares in the last quarter. Centaurus Financial Inc. acquired a new stake in Galectin Therapeutics during the 1st quarter valued at $34,000. Jane Street Group LLC acquired a new stake in Galectin Therapeutics during the 4th quarter valued at $40,000. Finally, Virtu Financial LLC increased its holdings in Galectin Therapeutics by 205.4% during the 4th quarter. Virtu Financial LLC now owns 39,169 shares of the company’s stock valued at $44,000 after purchasing an additional 26,345 shares in the last quarter. 12.24% of the stock is owned by institutional investors and hedge funds.
About Galectin Therapeutics
Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer.
- Five stocks we like better than Galectin Therapeutics
- Investing in Blue-Chip Stocks
- The most upgraded stocks in November have two things in common
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Monday.com rocked earnings like it’s the weekend
- Manufacturing Stocks Investing
- Plan to own one retailer? Make it this one
Receive News & Ratings for Galectin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.